Close Menu

NEW YORK (GenomeWeb) – Natera has filed a suit against Bio-Reference Laboratories claiming that the firm breached a contract with Natera when it launched and promoted a noninvasive prenatal test based on Illumina's technology, according to a research note issued this morning by investment bank Piper Jaffray.

Bio-Reference has been offering Natera's Panorama noninvasive prenatal screening test since 2013, but last month it launched its own NIPS, ClariTest, which is based on technology it licensed from Illumina.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
06
Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.